Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data

Eren Arslan Davulcu; Fatma Keklik Karadağ; Ayşenur Arslan; Zühal Demirci; Derya Demir; Nur Soyer; Fahri Şahin; Güray Saydam

doi:10.19161/etd.1310801

TR EN

Relaps ve refrakter T-hücreli lenfoma hastalarında pralatrexate kullanımı: gerçek yaşam verileri

Öz

Amaç: T-hücreli lenfomalar, non-Hodgkin lenfomaların kötü prognozlu bir alt tipidir ve tedavi seçenekleri sınırlıdır. Bir antimetabolit ilaç olan pralatrexate, relaps ve refrakter T-hücreli lenfoma tedavisinde onaylanmıştır. Gereç ve Yöntem: Çalışmamızda pralatreksat alan relaps ve refrakter T-hücreli lenfoma hastaları ilacın etkinlik ve güvenliliği açısından retrospektif olarak değerlendirilmiştir. Bulgular: Toplam 13 hasta alındı. Tanı anındaki ortanca yaş 63 olarak bulundu. En yaygın histolojik tipler, büyük hücre transformasyonu gösteren mikozis fungoides (%31) ve anjiyoimmünoblastik Thücreli lenfomaydı (%31). Pralatreksattan önceki medyan sistemik tedavi sayısı 2’ydi (1-6 aralığında). En sık görülen yan etki mukozitti (%54). Genel yanıt oranı %38'di (%15 tam remisyon ve %23 kısmi remisyon). Ortanca OS 32±6,5 ay ve PFS 6,78±1,6 aydı. Sonuç: Çalışmamız, pralatreksatın etkinliği ve güvenliği hakkında gerçek dünya verileri sağlamıştır ve sonuçlar mevcut literatürü desteklemektedir. Toksisitesi kabul edilebilir düzeydedir ve periferik Thücreli lenfomalar üzerinde önemli etkinliği vardır.

Anahtar Kelimeler

Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data

Abstract

Aim: T-cell lymphomas are a subtype of Non-Hodgkin lymphoma with a poor prognosis and treatment options are limited. Pralatrexate, an antimetabolite drug, has been approved for the treatment of relapsed and refractory T-cell lymphoma. Materials and Methods: Our study retrospectively evaluated relapsed and refractory T-cell lymphoma patients who received pralatrexate in terms of efficacy and safety of the drug. Results: A total of 13 patients were recruited. The median age at diagnosis was 63 years. The most common histologic types were mycosis fungoides with large cell transformation (31%) and angioimmunoblastic T-cell lymphoma (31%). The median number of prior systemic therapies before pralatrexate was 2 (range 1-6). The most common side effect was mucositis (54%). The overall response rate was 38% (15% complete remission and 23% partial remission). The median OS was 32±6.5 months and PFS was 6.78±1.6 months. Conclusion: Our study provided real-world data on the efficacy and safety of pralatrexate and supports current literature. This drug has acceptable toxicity and significant effectiveness on peripheral T-cell lymphomas.

Keywords

References

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood 2014;123:2636- 44.
Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol 2011;2011:623924.
Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019;393:229-240.
Petrich AM, Rosen ST. Peripheral T-cell lymphoma: new therapeutic strategies. Oncology (Williston Park) 2013;27:878-84.
Toner LE, Vrhovac R, Smith EA, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:924-32.
Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10- propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027-35.
Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010;16:3648-58.

Details

Primary Language

English

Subjects

Haematology

Journal Section

Research Article

Authors

Eren Arslan Davulcu ^*
Türkiye

Fatma Keklik Karadağ
Türkiye

Ayşenur Arslan
Türkiye

Zühal Demirci
Türkiye

Derya Demir
Türkiye

Nur Soyer
Türkiye

Fahri Şahin
Türkiye

Güray Saydam
Türkiye

Publication Date

June 12, 2023

Submission Date

December 25, 2022

Acceptance Date

January 21, 2023

Published in Issue

Year 2023 Volume: 62 Number: 2

DOI

https://doi.org/10.19161/etd.1310801

IZ

https://izlik.org/JA46ZJ45PJ

Cite

RIS / Bibtex

Vancouver

1.Eren Arslan Davulcu, Fatma Keklik Karadağ, Ayşenur Arslan, Zühal Demirci, Derya Demir, Nur Soyer, Fahri Şahin, Güray Saydam. Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data. EJM. 2023 Jun. 1;62(2):266-71. doi:10.19161/etd.1310801